MSH2 and neoplasm: The highest frequency (up to 33%) of EPCAM rearrangements was observed in the subset of MSI-H patients negative for germline MMR alterations and lacking MSH2 tumor expression [11,12], but the overall frequency of these rearrangements in series of HNPCC probands, unselected for mutational status or MSH2 tumor immunostaining, has not been evaluated.